Evaluating diagnostic strategies for early detection of cancer: the CanTest framework

Published on Dec 1, 2019in BMC Cancer2.933
· DOI :10.1186/s12885-019-5746-6
Fiona M Walter34
Estimated H-index: 34
(University of Cambridge),
Matthew Thompson32
Estimated H-index: 32
(UW: University of Washington)
+ 12 AuthorsJon Emery42
Estimated H-index: 42
(University of Melbourne)
Background Novel diagnostic triage and testing strategies to support early detection of cancer could improve clinical outcomes. Most apparently promising diagnostic tests ultimately fail because of inadequate performance in real-world, low prevalence populations such as primary care or general community populations. They should therefore be systematically evaluated before implementation to determine whether they lead to earlier detection, are cost-effective, and improve patient safety and quality of care, while minimising over-investigation and over-diagnosis.
  • References (33)
  • Citations (0)
📖 Papers frequently viewed together
35 Citations
5 Citations
12 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
#1Joshua D. Cohen (Johns Hopkins University)H-Index: 7
#2Lu Li (Johns Hopkins University)H-Index: 8
Last. Nickolas Papadopoulos (Johns Hopkins University)H-Index: 75
view all 42 authors...
Earlier detection is key to reducing cancer deaths. Here we describe a blood test that can detect eight common cancer types through assessment of the levels of circulating proteins and mutations in cell-free DNA. We applied this test, called CancerSEEK, to 1,005 patients with non-metastatic, clinically detected cancers of the ovary, liver, stomach, pancreas, esophagus, colorectum, lung, or breast. CancerSEEK tests were positive in a median of 70% of the eight cancer types. The sensitivities rang...
373 CitationsSource
If gastrointestinal cancer diagnosis is to be both timely and affordable in the future, the roles of health-care professionals need to be reframed. In this Perspectives, the authors consider how the relationship between medical specialists and generalists can be better integrated for optimal clinical outcomes and patient experience.
2 CitationsSource
#1Peter Ström (KI: Karolinska Institutet)H-Index: 8
#2Tobias Nordström (KI: Karolinska Institutet)H-Index: 12
Last. Martin Eklund (KI: Karolinska Institutet)H-Index: 13
view all 6 authors...
Abstract Background It has been shown that the Stockholm-3 model (S3M) outperforms prostate-specific antigen (PSA) as a screening tool for prostate cancer. Objective To update the S3M, to give a detailed account of the value of each predictor in the S3M, and to evaluate the S3M as a reflex test for men with PSA ≥3ng/ml. Design, setting, and participants During 2012–2015, the Stockholm-3 study evaluated the S3M relative to PSA as tests for Gleason score ≥7 prostate cancers among men aged 50–69 yr...
13 CitationsSource
3 CitationsSource
#1Reem A. Mustafa (McMaster University)H-Index: 30
#2Wojtek Wiercioch (McMaster University)H-Index: 12
Last. Holger J. Schünemann (McMaster University)H-Index: 109
view all 10 authors...
Abstract Objectives In this first of a series of five articles, we provide an overview of how and why healthcare-related tests and diagnostic strategies are currently applied. We also describe how our findings can be integrated with existing frameworks for making decisions that guide the use of healthcare-related tests and diagnostic strategies. Study Design and Setting We searched MEDLINE, references of identified articles, chapters in relevant textbooks, and identified articles citing classic ...
13 CitationsSource
#1Jan Y Verbakel (University of Oxford)H-Index: 11
#2Philip J. Turner (University of Oxford)H-Index: 9
Last. A Van den BruelH-Index: 8
view all 7 authors...
Objective Since 2008, the Oxford Diagnostic Horizon Scan Programme has been identifying and summarising evidence on new and emerging diagnostic technologies relevant to primary care. We used these reports to determine the sequence and timing of evidence for new point-of-care diagnostic tests and to identify common evidence gaps in this process. Design Systematic overview of diagnostic horizon scan reports. Primary outcome measures We obtained the primary studies referenced in each horizon scan r...
12 CitationsSource
#1Bjørn Hofmann (NTNU: Norwegian University of Science and Technology)H-Index: 24
#2H. Gilbert Welch (Dartmouth College)H-Index: 60
Although new diagnostics may advance the time of diagnoses in selected patients, they will increase the frequency of false alarms, overdiagnosis, and overtreatment in others. Bjorn Hofmann and H. Gilbert Welch explain how to minimise harm
20 CitationsSource
Controversy continues to roil around the role of PSA screening in prostate cancer. The authors review the available data and its quality and conclude that the evidence does not indicate that the benefits outweigh the harms.
28 CitationsSource
#1Juliet A. Usher-Smith (University of Cambridge)H-Index: 15
#2Stephen J. Sharp (University of Cambridge)H-Index: 72
Last. Simon J. Griffin (University of Cambridge)H-Index: 65
view all 3 authors...
The spectrum effect describes the variation between settings in performance of tests used to predict, screen for, and diagnose disease. In particular, the predictive use of a test may be different when it is applied in a general population rather than in the study sample in which it was first developed. This article discusses the impact of the spectrum effect on measures of test performance, and its implications for the development, evaluation, application, and implementation of such tests.
46 CitationsSource
#1Matthew Thompson (UW: University of Washington)H-Index: 32
#2Bernhard WeiglH-Index: 1
Last. Nicole Ide (UW: University of Washington)H-Index: 2
view all 4 authors...
Current frameworks for evaluating diagnostic tests are constrained by a focus on diagnostic accuracy, and assume that all aspects of the testing process and test attributes are discrete and equally important. Determining the balance between the benefits and harms associated with new or existing tests has been overlooked. Yet, this is critically important information for stakeholders involved in developing, testing, and implementing tests. This is particularly important for point of care tests (P...
7 CitationsSource
Cited By0
#1Fiona M Walter (University of Cambridge)H-Index: 34
#2Jon Emery (University of Melbourne)H-Index: 42